Verrica Pharmaceuticals (VRCA) Total Liabilities (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Total Liabilities of $22.7 million for Q1 2026, down 62.59% year-over-year from $60.8 million in Q1 2025, and up 1.53% quarter-over-quarter from $22.4 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Total Liabilities (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Total Liabilities history runs 10 years deep, the most recent figure standing at $22.7 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 62.59% year-over-year to $22.7 million; the TTM figure through Mar 2026 stood at $22.7 million (down 62.59% YoY), while the FY2025 annual figure was $22.4 million, down 65.02% from the prior year.
- Total Liabilities for Q1 2026 stood at $22.7 million, up from $22.4 million in the prior quarter.
- The five-year high for Total Liabilities was $67.0 million in Q3 2024, with the low at $3.8 million in Q1 2023.
- The 5-year median for Total Liabilities is $54.8 million (2023), against an average of $41.8 million.
- The sharpest annual moves came in 2023 and 2024: Total Liabilities tumbled 91.79% in 2023, then jumped 1608.38% in 2024.
- Verrica Pharmaceuticals' Total Liabilities stood at $4.7 million in 2022, then jumped by 1218.98% to $61.8 million in 2023, then gained by 3.49% to $64.0 million in 2024, then slumped by 65.02% to $22.4 million in 2025, then gained by 1.53% to $22.7 million in 2026.
- Business Quant data shows VRCA's Total Liabilities at $22.7 million in Q1 2026, $22.4 million in Q4 2025, and $57.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Verrica Pharmaceuticals | 104.71 Mn | 93.51 Mn | - | 31.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.71 Mn |
| Mar 31, 2026 | 22.73 Mn |
| Dec 31, 2025 | 22.39 Mn |
| Sep 30, 2025 | 57.94 Mn |
| Jun 30, 2025 | 56.59 Mn |
| Mar 31, 2025 | 60.75 Mn |
| Dec 31, 2024 | 63.99 Mn |
| Sep 30, 2024 | 66.98 Mn |
| Jun 30, 2024 | 65.31 Mn |
| Mar 31, 2024 | 64.80 Mn |
| Dec 31, 2023 | 61.83 Mn |
| Sep 30, 2023 | 54.85 Mn |
| Jun 30, 2023 | 6.80 Mn |
| Mar 31, 2023 | 3.79 Mn |
| Dec 31, 2022 | 4.69 Mn |
| Sep 30, 2022 | 4.38 Mn |
| Jun 30, 2022 | 47.10 Mn |
| Mar 31, 2022 | 46.20 Mn |
| Dec 31, 2021 | 47.52 Mn |
| Sep 30, 2021 | 47.90 Mn |